Skip to main content
    P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $124.67
    -0.16 (-0.13%)

    Market Cap: $8.55B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Protagonist Therapeutics Inc (PTGX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Protagonist Therapeutics (PTGX) has a market cap of $8.55B and an enterprise value of $8.05B. Revenue grew 163.69% over the last 12 months from the 12 months before. It kept 62.04% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 5.83% below the market cap, as cash exceeds debt.

    Market Cap$8.55B
    Enterprise Value$8.05B
    Latest price (Nov 17, 2026)$124.67

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.65% in the quarter ended Sep 30, 2026 and grew 3.65% a year over 2 years.

    Shares Outstanding66.36M
    Shares Change (YoY)+4.06%
    Shares Change (QoQ)+0.65%
    Share Count Growth (2Y CAGR)+3.65%

    Valuation Ratios

    Sales and book value multiples are 15.0x and 7.6x.

    P/E Ratio26.4x
    Forward P/E24.8x
    P/S Ratio15.0x
    Forward P/S15.1x
    P/B Ratio7.6x
    P/FCF Ratio75.8x
    P/OCF Ratio77.8x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 24.3x EBITDA and 71.2x free cash flow.

    EV / Earnings23.5x
    EV / Sales14.6x
    EV / EBITDA24.3x
    EV / FCF71.2x

    Price Statistics

    The stock is up 47.35% over 52 weeks and trades 10.61% below its 50-day average.

    Beta (1Y)0.94
    52-Week Change+47.35%
    1-Month Change-7.27%
    3-Month Change-19.54%
    6-Month Change+26.74%
    5-Year Change+364.86%
    10-Year Change+670.48%
    Total Return (1Y)+47.35%
    Total Return (3Y CAGR)+94.98%
    Total Return (5Y CAGR)+27.93%
    Return vs SPY (1Y)+36.17%
    Max Drawdown (1Y)-21.40%
    Max Drawdown (3Y)-31.58%
    Sharpe Ratio (1Y)0.98
    Correlation with SPY (1Y)0.32
    50-Day Average$139.46
    200-Day Average$119.71
    52-Week Range$77.00 to $160.81
    RSI (14 Days)32.5
    Average Volume (20 Days)586.97K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 19.85x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio19.85x
    Quick Ratio19.85x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 31.55% over the last 12 months, against a 5-year average of -20.96%.

    Return on Equity (ROE)31.55%
    Return on Assets (ROA)29.85%
    ROE (5Y Average)-20.96%
    ROA (5Y Average)-18.42%
    ROIC (5Y Average)-25.72%
    Asset Turnover0.60x

    Taxes

    Income tax took 2.28% of pretax income over the last 12 months.

    Income Tax (TTM)$7.99M
    Effective Tax Rate2.28%

    Scores

    PTGX has an Altman Z-Score of 82.93, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score82.93
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $551.69M over the last 12 months.

    Revenue$551.69M
    Revenue Growth (YoY)+163.69%
    Gross Profit$550.59M
    Operating Income$323.10M
    Pretax Income$350.25M
    Net Income$342.26M
    Reported EPS (TTM)$4.72

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 93.91% of the $1.15B in total assets.

    Cash and Equivalents$498.30M
    Total Debt$0
    Net Cash$498.30M
    Net Cash Per Share$7.51
    Working Capital$1.05B
    Shareholder Equity$1.08B
    Book Value Per Share$16.35
    Total Assets$1.15B
    Total Liabilities$61.64M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $764.00K of capital spending, operating cash flow left $109.15M of free cash flow.

    Operating Cash Flow$109.91M
    Capital Expenditures$764.00K
    Free Cash Flow$109.15M
    FCF Per Share$1.69
    Depreciation and Amortization$6.08M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 58.56%.

    Gross Margin99.80%
    Operating Margin58.56%
    Pretax Margin63.49%
    Net Margin62.04%
    FCF Margin19.78%

    Growth

    Revenue grew 20.07% a year over 3 years.

    Revenue Growth (3Y CAGR)+20.07%
    Revenue Growth (5Y CAGR)+9.96%
    Book Value Per Share Growth (2Y CAGR)+33.22%
    Tangible Book Per Share Growth (2Y CAGR)+33.22%

    Revenue and profit by year

    Dividends and Yields

    PTGX does not pay a dividend. Its free cash flow yield is 1.32%.

    Earnings Yield3.79%
    FCF Yield1.32%
    Buyback Yield-0.60%
    Shareholder Yield-0.60%

    Peer Position

    Against 3 similar companies, PTGX has the lowest P/E.

    P/E Ratio26.4x vs 64.7x median
    P/S Ratio15.0x vs 11.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+163.69% vs +20.11% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 126.36% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+126.36%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PTGX

    What is PTGX's market cap?

    Protagonist Therapeutics has a market cap of $8.55B. Its enterprise value, which adds debt and subtracts cash, is $8.05B.

    What is PTGX's P/E ratio?

    Protagonist Therapeutics has a trailing P/E ratio of 26.4x and a forward P/E of 24.8x.

    How many shares of PTGX are outstanding?

    Protagonist Therapeutics has 66.36M shares outstanding. The count is up 4.06% from a year earlier.

    Does PTGX pay a dividend?

    No. Protagonist Therapeutics does not pay a dividend.

    How much debt does PTGX have?

    Protagonist Therapeutics has $0 of total debt and $498.30M of cash and equivalents, a net cash position of $498.30M.